ARTICLE | Company News
CRXL, Centocor in deal
August 16, 2001 7:00 AM UTC
Centocor will develop and commercialize Crucell's CD46-specific human antibodies for the treatment of cancer. Centocor is responsible for global development and manufacturing and has global commercial...